Пожалуйста, используйте этот идентификатор, чтобы цитировать или ссылаться на этот ресурс: http://hdl.handle.net/20.500.12701/1710
Полная запись метаданных
Поле DCЗначениеЯзык
dc.contributor.authorBissell, Karen-
dc.contributor.authorEllwood, Philippa-
dc.contributor.authorEllwood, Eamon-
dc.contributor.authorChiang, Chen-Yuan-
dc.contributor.authorMarks, Guy B.-
dc.contributor.authorSony, Asma El-
dc.contributor.authorAsher, Innes-
dc.contributor.authorBillo, Nils-
dc.contributor.authorPerrin, Christophe-
dc.date.accessioned2022-03-23T05:40:58Z-
dc.date.available2022-03-23T05:40:58Z-
dc.date.issued2019-02-19-
dc.identifier.urihttps://doi.org/10.3390/ijerph16040605-
dc.identifier.urihttp://hdl.handle.net/20.500.12701/1710-
dc.description.abstractPatients with asthma need uninterrupted supplies of affordable, quality-assured essential medicines. However, access in many low- and middle-income countries (LMICs) is limited. The World Health Organization (WHO) Non-Communicable Disease (NCD) Global Action Plan 2013–2020 sets an 80% target for essential NCD medicines’ availability. Poor access is partly due to medicines not being included on the national Essential Medicines Lists (EML) and/or National Reimbursement Lists (NRL) which guide the provision of free/subsidised medicines. We aimed to determine how many countries have essential asthma medicines on their EML and NRL, which essential asthma medicines, and whether surveys might monitor progress. A cross-sectional survey in 2013–2015 of Global Asthma Network principal investigators generated 111/120 (93%) responses—41 high-income countries and territories (HICs); 70 LMICs. Patients in HICs with NRL are best served (91% HICs included ICS (inhaled corticosteroids) and salbutamol). Patients in the 24 (34%) LMICs with no NRL and the 14 (30%) LMICs with an NRL, however no ICS are likely to have very poor access to affordable, quality-assured ICS. Many LMICs do not have essential asthma medicines on their EML or NRL. Technical guidance and advocacy for policy change is required. Improving access to these medicines will improve the health system’s capacity to address NCDs.ru_RU
dc.language.isoenru_RU
dc.publisherMDPIru_RU
dc.relation.ispartofseriesVolume 16, Issue 4;Volume 16, Issue 4-
dc.subjectessential medicinesru_RU
dc.subjectaccessru_RU
dc.subjectnoncommunicable diseasesru_RU
dc.subjectasthmaru_RU
dc.subjectinhaled corticosteroidsru_RU
dc.subjectbronchodilatorsru_RU
dc.subjectnational reimbursement listru_RU
dc.titleEssential Medicines at the National Level: The Global Asthma Network’s Essential Asthma Medicines Survey 2014ru_RU
dc.typeArticleru_RU
Располагается в коллекциях:International Journal of Environmental Research and Public Health

Файлы этого ресурса:
Файл Описание РазмерФормат 
10.3390_ijerph16040605.pdf.pdf343,92 kBAdobe PDFПросмотреть/Открыть


Все ресурсы в архиве электронных ресурсов защищены авторским правом, все права сохранены.